

**Application
for
United States Letters Patent**

RECEIVED

To all whom it may concern:

Be it known that Robert H. DeBellis and Bernard F. Erlanger

have invented certain new and useful improvements in

METHODS OF TREATING SICKLE CELL DISEASE

of which the following is a full, clear and exact description.

METHODS OF TREATING SICKLE CELL DISEASE

5 Throughout this application, various references are
referred to within parentheses. Disclosures of these
publications in their entireties are hereby incorporated
by reference into this application to more fully describe
the state of the art to which this invention pertains.
10 Full bibliographic citation for these references may be
found immediately preceding the claims.

Background of the Invention

15 Despite considerable knowledge regarding the etiology of
sickle cell disease, effective treatment has been
elusive. Modalities for therapy have largely been
directed at symptomatology. This disease is a major cause
of illness in black populations throughout the world; it
is estimated that 1 in 600 black individuals suffer from
20 this disorder and that 8% are heterozygous carriers of
the trait. Moreover, an equal number of individuals
suffer from sickle cell equivalents (sickle cell-
hemoglobin C disease and sickle cell- β -thalassemia) (1).

25 Since the discovery of the etiology of sickle cell
disease in 1949 by Pauling and his colleagues (2), a vast
literature has grown in the fields of biochemistry,
molecular biology and genetics regarding the mechanisms
involved in the aggregation or polymerization of
30 hemoglobin S ("HbS"), the sickling of intact erythrocytes
and the inhibition of sickling by other hemoglobins (see
review by Bunn) (3).

35 Despite the voluminous literature, little progress has
been made in the treatment of this disabling disorder.
The ideal treatment would involve replacement of the gene
for β^s production with an innocuous substitution. Many
laboratories are pursuing this goal, to date none

FOIA b 7 - Excluded

5

10

15

20

25

Summary of the Invention

5 This invention provides a method of treating a subject afflicted with sickle cell disease which comprises administering to the subject an amount of an antiviral agent effective to inhibit sickling of a cell in the subject, so as to thereby treat the subject afflicted with sickle cell disease.

10 This invention provides a method of inhibiting polymerization of hemoglobin which comprises contacting the hemoglobin with an amount of an antiviral agent effective to inhibit polymerization of the hemoglobin, so as to thereby inhibit polymerization of the hemoglobin.

15 This invention provides a method of inhibiting sickling of a cell which comprises contacting the cell with an amount of an antiviral agent effective to inhibit polymerization of hemoglobin in the cell, so as to
20 thereby inhibit sickling of the cell.

25 This invention provides a method of determining whether an antiviral agent is capable of treating a subject afflicted with sickle cell disease which comprises: (a) obtaining a suitable sample of cells from a subject afflicted with sickle cell disease; (b) subjecting the sample to conditions such that the cells in the sample sickle; and (c) comparing the amount of sickling of the cells in the presence of the antiviral agent with the
30 amount of sickling of the cells in the absence of the antiviral agent, wherein an absence of sickling or a reduction in the amount of sickling in the cells in the presence of the antiviral agent compared with the amount of sickling of the cells in the absence of the antiviral agent indicates that the antiviral agent is capable of
35 treating a subject afflicted with sickle cell disease.

Brief Description of the Figures

Figure 1

Effect of various concentrations of acyclovir on the
5 aggregation of deoxygenated hemoglobin S.

Figure 2

(A) Sickling of deoxygenated erythrocytes in the absence
of added reagents, i.e. the control. (B) Sickling of
10 deoxygenated erythrocytes in the presence of 0.2 mg/ml of
acyclovir. (C) Sickling of deoxygenated erythrocytes in
the presence of 0.3 mg/ml of acyclovir. (D) Sickling of
deoxygenated erythrocytes in the presence of 0.4 mg/ml of
acyclovir. (E) Erythrocytes from the same patient under
15 aerobic conditions.

Figure 3

Effect of compounds, including acyclovir and
valacyclovir, on the aggregation of deoxygenated
20 hemoglobin S. (Legend: -O- control; -●- valacyclovir; -x-
acyclovir; -Δ- glycopage x; -▲- Diphen).

Detailed Description of the Invention

5 This invention provides a method of treating a subject afflicted with sickle cell disease which comprises administering to the subject an amount of an antiviral agent effective to inhibit sickling of a cell in the subject, so as to thereby treat the subject afflicted with sickle cell disease.

10 As used herein, "treating" means either slowing, stopping or reversing the progression of the sickling of a cell. In the preferred embodiment, "treating" means reversing the progression to the point of eliminating the presence of sickled cells. As used herein, "treating" also means
15 the reduction in the amount of polymerization of hemoglobin or the amelioration of symptoms associated with sickle cell disease.

20 As used herein, "afflicted with sickle cell disease" means that the subject has at least one sickle cell. As used herein, a "sickle cell" includes a cell which is an abnormal, crescent-shaped erythrocyte that contains sickle cell hemoglobin from a subject with sickle cell disease. "Sickling" includes the process whereby a normal-
25 shaped cell becomes crescent-shaped.

As used herein, "administering" may be effected or performed using any of the methods known to one skilled in the art. The methods may comprise intralesional,
30 intramuscular, subcutaneous, intravenous, intraperitoneal, liposome mediated, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic means of delivery.

35 As used herein, "effective amount" means an amount in sufficient quantities to accomplish the specific task, i.e., either treat the subject, reduce or prevent

sickling of cells and/or reduce or prevent polymerization of hemoglobin. A person of ordinary skill in the art can perform simple titration experiments to determine what amount is required to treat the subject.

5

The amount of the antiviral agent will vary depending on the subject and upon the particular route of administration used. Based upon the antiviral agent, the amount can be delivered continuously, such as by continuous pump, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple amounts of a particular antiviral agent can be determined without undue experimentation by one skilled in the art.

15

In one embodiment the effective amount of the compound comprises from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. In another embodiment, the effective amount comprises from about 100 ng/kg to about 50 mg/kg body weight of the subject. In another embodiment, the effective amount comprises from about 1 µg/kg to about 10 mg/kg body weight of the subject. In a further embodiment, the effective amount comprises from about 100 µg/kg to about 1 mg/kg body weight of the subject. For example, amounts can range from 5 mg/kg to 10 mg/kg body weight of the subject administered intravenously; or 400 mg/kg to 800 mg/kg body weight of the subject administered orally; or 0.2 mg/ml to 0.4 mg/ml *in vitro*.

30

As used herein, "antiviral agent" includes a compound that inhibits the replication of viruses in cells, tissues, or organisms. Examples include but are not limited to Acyclovir (2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one), Valacyclovir (L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, Pencyclovir (9-[4-hydroxy-3-

35

(hydroxymethylbutyl]]guanine), Famcyclovir (2-[2-(amino-9H-purin-9-yl)]ethyl-1,3-propanediol diacetate), Ribavirin (1-beta-D-ribofuanosyl-1-H-1,2,4-triazol-3-carboxamide), Lamivudine ((2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidine-2-one), Amantadine (1-amantanamine hydrochloride), and Rimantadine (α -methyltricyclo (3.3.1.1/3.7 decane-1-methylamine hydrochloride).

As used herein, "inhibits" means that the amount is reduced. In a preferred embodiment, inhibits means that the amount is reduced 100%.

This invention provides a method of inhibiting polymerization of hemoglobin which comprises contacting the hemoglobin with an amount of an antiviral agent effective to inhibit polymerization of the hemoglobin, so as to thereby inhibit polymerization of the hemoglobin.

As used herein, "polymerization" includes the process of forming a polymer from many monomeric units of hemoglobin. A polymer may be formed by any chemical bonding interaction between or among molecules, i.e. covalent, ionic, or van der Waals. As used herein, "aggregation" and "polymerization" may be used interchangeably.

In one embodiment of the above method, the hemoglobin is present in a cell and the contacting is effected by contacting the cell with the antiviral agent.

This invention provides a method of inhibiting sickling of a cell which comprises contacting the cell with an amount of an antiviral agent effective to inhibit polymerization of hemoglobin in the cell, so as to thereby inhibit sickling of the cell.

5 This invention provides a method of determining whether
an antiviral agent is capable of treating a subject
afflicted with sickle cell disease which comprises: (a)
obtaining a suitable sample of cells from a subject
10 afflicted with sickle cell disease; (b) subjecting the
sample to conditions such that the cells in the sample
sickle; and (c) comparing the amount of sickling of the
cells in the presence of the antiviral agent with the
amount of sickling of the cells in the absence of the
15 antiviral agent, wherein an absence of sickling or a
reduction in the amount of sickling in the cells in the
presence of the antiviral agent compared with the amount
of sickling of the cells in the absence of the antiviral
agent indicates that the antiviral agent is capable of
treating a subject afflicted with sickle cell disease.

20 This invention provides a method of determining whether
an antiviral agent is capable of inhibiting sickling of
a cell which comprises: (a) obtaining a suitable sample
of cells from a subject afflicted with sickle cell
disease; (b) subjecting the sample to conditions such
that the cells in the sample sickle; and (c) comparing
the amount of sickling of the cells in the presence of
the antiviral agent with the amount of sickling of the
25 cells in the absence of the antiviral agent, wherein an
absence of sickling or a reduction in the amount of
sickling in the cells in the presence of the antiviral
agent compared with the amount of sickling of the cells
in the absence of the antiviral agent indicates that the
30 antiviral agent is capable of inhibiting sickling of the
cell.

35 This invention provides a method of determining whether
an antiviral agent is capable of inhibiting
polymerization of hemoglobin which comprises: (a)
obtaining a suitable sample of hemoglobin from a subject
afflicted with sickle cell disease; (b) subjecting the

FOIA b 7 - EXEMPT

sample to conditions such that the hemoglobin polymerizes; and (c) comparing the amount of turbidity of the sample in the presence of the antiviral agent with the amount of turbidity of the sample in the absence of the antiviral agent, wherein an absence or reduction in the amount of turbidity in the sample in the presence of the antiviral agent compared with the amount of turbidity in the sample in the absence of the antiviral agent indicates that the antiviral agent is capable of inhibiting polymerization of hemoglobin.

One skilled in the art would know under what conditions that hemoglobin polymerizes. One example is the condition wherein oxygen tension is reduced. Another example is the condition wherein the erythrocyte cell is contacted with a reducing agent. One of ordinary skill in the art will know what methods to use in order to reduce oxygen tension. A "reducing agent" includes an agent which is capable of removing oxygen bound to the heme group in hemoglobin. An example of a reducing agent is Sodium dithionite ($\text{Na}_2\text{S}_2\text{O}_4$).

One skilled in the art would know methods to use to compare the amount of sickling in samples. One example is a visual comparison. Such visual comparison may be done in several ways including but not limited to under a microscope and with the naked eye.

One skilled in the art would know methods to use to compare the turbidity in samples. One example is the use of a spectrophotometer. As used herein, "turbidity" includes the opacity caused by suspended particles or cells in a solution wherein a higher turbidity indicates that the sample has more polymerization or aggregation than a sample with lower turbidity.

In one embodiment of the above methods, the hemoglobin is

09224-04060
F0300-ET4300

5 In one embodiment of the above methods, the cell is an erythrocyte cell. As used herein, "erythrocyte cell" may be a red blood cell. In another embodiment of the above methods, the suitable sample is a sample of erythrocyte cells. In a further embodiment of the above methods, the cell is present in the subject and the contacting is effected by administering the antiviral agent to the
10 subject.

In one embodiment of the above methods, the sickle cell disease includes but is not limited to sickle cell anemia, sickle β -thalassemia, sickle cell-hemoglobin C disease and any other sickle hemoglobinopathy in which hemoglobin S interacts with a hemoglobin other than hemoglobin S. "Sickle hemoglobinopathy" is an abnormality of hemoglobin which results in sickle cell disease or sickle variants.

In one embodiment of the above methods, the subject is a mouse, rat, dog, guinea pig, ferret, rabbit, primate, or human being. As used herein, "subject" means any animal or artificially modified animal capable of being afflicted with sickle cell disease. In the preferred embodiment, the subject is a human being.

The routes of administration include but are not limited to intralesional, intramuscular, subcutaneous, intravenous, intraperitoneal, liposome mediated, transmucosal, intestinal, topical, nasal, oral, anal, ocular and otic delivery.

This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

409040-243330

EXPERIMENTAL DETAILS

A. Materials and Methods

Solutions of acyclovir were prepared from "Acyclovir for Injection" (ESI Lederle, Philadelphia, PA) by first dissolving 500 mg in 2.5 ml distilled water. This solution of 200 mg/ml is stored in the refrigerator. Before use, it is warmed to 37°C to maintain a clear solution. An aliquot is diluted 40-fold in distilled water and the various solutions used in the experiments prepared in PBS.

Using methodologies modeled after those previously developed in other laboratories, assays to measure *in vitro* aggregation of a solution of hemoglobin S ("HbS") (13, 14) and *in vitro* sickling of intact HbS cells (15) were carried out as follows.

Inhibition of Aggregation of Hemoglobin S

To a 10 mm cuvette (Type 9GL14S, Septum seal, Uvonic Instruments, Plainview, N.Y. 11803) containing 0.9 ml of 1.8M phosphate buffer, pH 9.4, was added 5 mg of $\text{Na}_2\text{S}_2\text{O}_3$. The cuvette was capped and two #25 hypodermic needles were inserted through the soft plastic seals. Nitrogen was passed over the surface of the solution for 15 minutes to drive off oxygen; the cuvette was then gently shaken to dissolve the $\text{Na}_2\text{S}_2\text{O}_3$. The cuvette was then placed in an ice bath to bring the solution to 4°C and 0.1 ml of a 2 g/dl HbS solution (13, 14) was added through the plastic diaphragm with a Hamilton air-tight syringe. The temperature of the solution in the cuvette was raised by placing it in a 30°C bath and then into a spectrophotometer in which the increase in turbidity was measured with time at 700 nm. A control curve was obtained after which the course of turbidity was measured in the presence of the various reagents including

acyclovir (Lederle, for injection; dilutions were in PBS) and valacyclovir. The latter was extracted with phosphate buffer from tablets of Valtrex (Glaxo Wellcome).

5 Inhibition of Sickling of Intact Erythrocytes by Acyclovir

The procedure used was essentially that of Cerami and Manning (15). The source of the red cells was human blood in which HbS represented essentially 100% of the total
10 hemoglobin as determined by electrophoresis on a cellulose acetate membrane in a Supre-Heme® Tris-EDTA-boric acid buffer (Helena Laboratories, Beaumont, TX).

Ten microliters of blood was diluted to 5 ml with PBS and
15 1 ml aliquots were distributed into the same type of cuvettes used to study hemoglobin S aggregation (see above). Two #25 hypodermic needles were inserted into each plastic diaphragm and nitrogen was passed over the surface of the erythrocyte suspension for 15 minutes with
20 periodic gentle shaking. The hypodermic needles were removed and the sealed cuvettes were left for 2 hours at room temperature. The control cuvette was treated identically except that the cap was loosened for the 2 hour period.

25 Then 250 μ l of 10% buffered formalin (Metpath) was added to the cell suspensions, which were allowed to stand at room temperature for 15 minutes. The cell suspensions were then sedimented by centrifugation, suspended in 100
30 μ l of PBS and examined under the microscope.

B. Results

35 Inhibition of Aggregation of Hemoglobin S at Low Oxygen Tension

Aggregation of soluble HbS occurred in response to

lowering of oxygen tension (control, Figure 1 and Figure 3) as did inhibition by hemoglobin A (not shown). Two antiviral agents, acyclovir and valacyclovir, were identified as inhibiting *in vitro* aggregation of HbS in a similar fashion. The results for acyclovir are shown in Figure 1. The results for both acyclovir and valacyclovir are shown in Figure 3.

Inhibition of Erythrocyte Sickling

Erythrocytes were taken from an individual in whom 95+% of total hemoglobin was HbS. The erythrocytes were placed under low oxygen tension in the absence or presence of acyclovir at concentrations of 0.2, 0.3 and 0.4 mg/ml. The erythrocytes were then formalin-fixed and examined under a microscope. In Figure 2A (the control), extensive sickling is apparent. Minimal sickling occurred at acyclovir concentrations of 0.2 mg/ml (Figure 2B) and 0.3 mg/ml (Figure 2C); essentially no sickling is seen in the presence of 0.4 mg/ml acyclovir (Figure 2D). Figure 2E represents erythrocytes from the same patient under aerobic conditions. Similar results were obtained with valacyclovir.

C. Discussion

In a screen of many therapeutic agents for their ability to inhibit aggregation of HbS, acyclovir and valacyclovir were found to be effective. They were active at relatively low concentrations compared, for example, with KCNO (15, 16) in which a concentration of 2.4 mg/ml was used, i.e. more than 10X the effective concentration of acyclovir (Figure 2). Moreover, there is experimental evidence that acyclovir is actively transported into erythrocytes via a nucleobase transporter rather than by a concentration-dependent simple diffusion (17).

It is also worth noting that the erythrocyte sickling experiments (Figure 2) were carried out essentially in the absence of oxygen. Clinically, sickling occurs under milder hypoxic conditions with oxygen tensions as high as 45 mm (18). And it has been reported that recurrence of symptoms of sickle cell disease can be prevented by keeping the proportion of sickling cells at levels as high as 60% by transfusion (19). We are well below 60% sickling at our lowest acyclovir concentration (Figure 2B). There is a good possibility, therefore, that even lower concentrations of acyclovir will be effective in preventing sickle cell crises. Finally, acyclovir caused no significant change in oxygen affinity or Hill coefficient in experiments with human hemoglobin (J.E. Knapp and W.E Royer, Jr., personal communication).

5

10

15

20

1090710 27732360

References

1. Steinberg, M.H. (1999), "Management Of Sickle Cell Disease", N. Engl. J. Med. 340: 1021-1030.
- 5 2. Pauling, L., H.A. Itano, S.J. Sinpur, I.C. Wells (1945), "Sickle Cell Anemia, A Molecular Disease", Science 110: 543-545.
- 10 3. Bunn, H.F. (1997), "Pathogenesis And Treatment Of Sickle Cell Disease", N. Engl. J. Med. 337: 762-769.
- 15 4. Dover, G.J., R.K. Humphries, J.G. Moore, T.J. Ley, N.S. Young, S. Charache, A.W. Nienhuis (1986), "Hydroxyurea Induction Of Hemoglobin F Production In Sickle Cell Disease; Relationship Between Cytotoxicity And F Cell Production", Blood 67: 735-738.
- 20 5. Charache, S., G.J. Dover, M.A. Moyer, J.W. Moore (1987), "Hydroxyurea-induced Augmentation Of Fetal Hemoglobin Production In Patient With Sickle Cell Anemia", Blood 69: 109-116.
- 25 6. Ballas, S.K., G.J. Dover, S. Charache (1989), "Effect Of Hydroxyurea On The Rheological Properties Of Sickle Erythrocytes In Vivo", Am. J. Hemotol. 32: 104-111.
- 30 7. Rogers, G.P., G.J. Dover, C.T. Noguchi, A.N. Schecter, A.W. Nienbuis (1990), "Hemotologic Responses Of Patients With Sickle Cell Disease To Treatment With Hydroxyurea", N. Engl. J. Med. 322: 1037-1045.
- 35 8. Goldberg, M.A., C. Brugnara, G.J. Dover, L. Shapira, S. Charache, H.F. Bunn (1990), "Treatment Of Sickle Cell Anemia With Hydroxyurea And Erythropoietin", N.

TO344-ETH3360

Engl. J. Med. 323: 366-372.

- 5 9. Orringer, E.P., D.S. Blythe, A.E. Johnson, G. Phillips, Jr., G.J. Dover, J.C. Park (1991), "Effects Of Hydroxyurea On Hemoglobin F And Water Content In The Red Blood Cells Of Dogs And Patients With Sickle Cell Anemia", Blood 78: 212-216.
- 10 10. Charache, S., M.C. Terrin, R.D. Moore, G.J. Dover, F.B. Barton, S.V. Eckert, R.P. McMahon, D.R. Bonds (1995), "Effect Of Hydroxyurea On The Frequency Of Painful Crises In Sickle Cell Anemia", N. Engl. J. Med. 332: 1317-1322.
- 15 11. Charache, S., F.B. Barton, R.D. Moore, M.L. Terrin, M.H. Steinberg, G.J. Dover, S.K. Ballas, R.P. McMahon, O. Castro, E.P. Orringer (1996), "Hydroxyurea And Sickle Cell Anemia: Clinical Utility Of A Myelosuppressive 'Switching' Agent: The Multicenter Study of Hydroxyurea In Sickle Cell Anemia", Medicine (Baltimore) 75: 300-326.
- 20 12. Ferster, A., C. Vermynen, G. Cornu, M. Buyse, F. Corazza, C. Devalck, P. Fondu, M. Toppet, E. Sariban (1996), "Hydroxyurea For Treatment Of Severe Sickle Cell Anemia: A Pediatric Clinical Trial", Blood 88: 1960-1964.
- 25 13. Huisman, T.H.J. and A.M. Dozy (1965), "Studies On The Heterogeneity Of Hemoglobin. IX. The Use Of Tris (hydroxymethyl) aminomethane.HCl In The Ion Exchange Chromatography Of Hemoglobins", J. Chromatog. 19: 160-169.
- 30 14. Adachi, K., M. Ozgue, T. Asakura (1980), "Nucleation-Controlled Aggregation Of Deoxyhemoglobin S Participation Of Hemoglobin A In The Aggregation Of
- 35

2025 RELEASE UNDER E.O. 14176

15. Cerami, A., and J.M. Manning (1971), "Potassium Cyanate As An Inhibitor Of The Sickling Of Erythrocytes In Vitro", Proc. Natl. Acad. Sci. USA 68: 1180-1183.
16. Gillette, P.N., C.M. Peterson, S.L. Yang, A. Cerami (1974), "Sodium Cyanate As A Potential Treatment For Sick Cell Disease", N. Eng. J. Med. 290: 654-660.
17. Mahony, W.B., B.A. Domin, R.T. McConnell, T.P. Zimmerman (1998), "Acyclovir Transport Into Human Erythrocytes" J. Biol. Chem. 263: 9285-9291.
18. Hahn, E.V., and E.B. Gillespie (1927), "Sickle Cell Anemia: Report Of A Case Greatly Improved By Splenectomy: Experimental Studies Of Sickle Cell Formation", Arch. Intern. Med. 39: 233-254.
19. Charache, S., and C.L. Conley (1964), "Rate Of Sickling Of Red Cells During Deoxygenation Of Blood From Persons With Various Sickling Disorders", Blood 24: 25-48.